Immunic presses ahead with MS drug despite Phase II endpoint miss
Immunic will continue developing its multiple sclerosis (MS) drug, vidofludimus calcium (IMU-838), despite a Phase II trial missing its primary…
Central Nervous System
-
-
Neurocrine begins Phase III programme for schizophrenia treatment
Neurocrine Biosciences has commenced a Phase III registrational programme to assess investigational oral muscarinic M4 selective orthosteric agonist NBI-1117568 as…
-
Therini Bio reports data from trial of THN391 for neurodegenerative conditions
US-based biotechnology company Therini Bio has reported positive results from a Phase Ia trial of THN391, a potential treatment for…
-
BMS’ schizophrenia therapy fails in Phase III trial as an adjunctive treatment
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported topline outcomes from the Phase III ARISE trial of Cobenfy as…
-
Alector concludes enrolment in Phase II trial of Alzheimer’s treatment
Alector has completed subject enrolment in the 76-week, randomised, Phase II PROGRESS-AD trial, which is assessing the efficacy and safety…
-
Neuren confirms Phase III trial goals for PMS drug NNZ-2591
Australia-based Neuren Pharmaceuticals has confirmed the primary goals for its double-blind, single Phase III pivotal trial of its drug NNZ-2591…
-
Alzheon’s Alzheimer’s pill fails in Phase III trial
US-based Alzheon’s Alzheimer’s disease pill has failed in a Phase III trial, but the biopharma still holds hope for the…
-
Parkinson’s Disease Awareness Month: Burden of disease
The month of April is dedicated to raising awareness of Parkinson’s disease (PD), the main aim of which is to…
-
AAN 2025: J&J reveals data for nipocalimab, showing long-term disease control in MG
On 8 April, at the 2025 American Academy of Neurology (AAN) meeting, Johnson & Johnson (J&J) announced results from additional…
-
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
Following the launch of the first disease-modifying therapies (DMTs) for Alzheimer’s disease (AD), a key theme at the AD/PD 2025…
